Skip to content
Screener

Operating Income at other companies

Schrodinger logo
SchrodingerSDGR
-$41.55M+21.5%
Twist Bioscience Corporation logo
Twist Bioscience CorporationTWST
-$45.86M-10.4%
Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
-$134.97M+23.4%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
-$58.55M-0.7%
Absci Corporation logo
Absci CorporationABSI
-$30.85M-11.2%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$31.52M-63.2%

Other financials

Income statement

See full
Revenue$4.1M-76.3%
Net income-$55.4M-59.6%
EPS (diluted)-$0.18-50.0%

Balance sheet

See full
Cash & equivalents$145.1M+23.5%
Total debt$135.6M-4.5%
Total equity$896.0M-11.0%
Total assets$1.3B-6.7%

Cash flow

See full
Operating cash flow-$33.5M-190%
CapEx$2.1M-84.0%
Free cash flow-$37.4M-68.3%

Valuation

See full
Market cap$1.99B+62.2%
Enterprise value$1.98B+58.2%
P/S30.1×-7.3×

Profitability

See full
Operating margin-340.3%-127pp
Net margin-248.8%-83.6pp
FCF margin-238.9%-90.9pp

Returns & leverage

See full
Return on equity-17.3%+2.1pp
Debt / equity0.2×0.0×
Current ratio12.8×+1.7×

Where this comes from

Reported directly by AbCellera Biologics Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: AbCellera Biologics Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:28 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001703057-26-000046
Line itemThree months ended June 30, 2025Three months ended June 30, 2026Six months ended June 30, 2025Six months ended June 30, 2026
Sales, general, and administrative(1)21,98613,85041,05426,185
Depreciation and amortization5,4706,99010,80113,828
Total operating expenses66,66966,827133,566132,662
Loss from operations(49,585)(62,777)(112,246)(120,300)
Other (income) expense:
Interest and other(9,549)42(15,073)(3,606)
Grants and incentives(3,692)(3,854)(7,845)(8,193)
Total other income(13,241)(3,812)(22,918)(11,799)

Item 1. Financial Statements (Unaudited)

FAQ

What is AbCellera Biologics Inc.'s operating income?
AbCellera Biologics Inc. (ABCL) reported operating income of -$62.78M in Q2 2026.
How has AbCellera Biologics Inc.'s operating income changed year-over-year?
AbCellera Biologics Inc.'s operating income decreased by 26.6% year-over-year, from -$49.59M to -$62.78M.
What is the long-term trend for AbCellera Biologics Inc.'s operating income?
Over 3 years (2021 to 2025), AbCellera Biologics Inc.'s operating income has grown at a 2.0% compound annual growth rate (CAGR), from $204.5M to -$217.11M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about AbCellera Biologics Inc.'s operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude